Inactive Instrument

Pain Therapeutics, Inc. Stock price Nasdaq

Equities

US69562K5065

Biotechnology & Medical Research

Sales 2024 * - Sales 2025 * 300M Capitalization 883M
Net income 2024 * -92M Net income 2025 * 120M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.94 x
P/E ratio 2024 *
-10.2 x
P/E ratio 2025 *
12.2 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.82%
More Fundamentals * Assessed data
Dynamic Chart
Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam MT
Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials CI
Cassava Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Cassava Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Cassava Sciences, Inc. Reports Results of Two-Year Clinical Safety Study of Simufilam, an Investigational Oral Drug for the Proposed Treatment of Alzheimer?s Disease Dementia CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2000 Index CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 3000 Index CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Index CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell Small Cap Completeness Index CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell Small Cap Comp Growth Index CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 3000 Growth Index CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Growth Index CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 3000E Index CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 3000E Growth Index CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2000 Dynamic Index CI
More news
Managers TitleAgeSince
Chief Executive Officer 64 98-04-30
Director of Finance/CFO 55 18-09-30
Chief Tech/Sci/R&D Officer - 21-01-03
Members of the board TitleAgeSince
Chief Executive Officer 64 98-04-30
Director/Board Member 86 03-02-28
Director/Board Member 76 07-12-06
More insiders
Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas. The Company is engaged in the detection and treatment of neurodegenerative diseases, such as Alzheimer's disease. The Company develops pharmaceutical product candidates that offer improvements to patients and healthcare professionals. The Company has two biopharmaceutical assets under development, including its lead therapeutic product candidate, called simufilam, is a oral treatment for Alzheimer's disease dementia, which is under Phase III clinical studies; and its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam is a proprietary small molecule (oral) drug, which targets an altered form of a protein called filamin A (FLNA) in the Alzheimer's brain. SavaDx is designed as an antibody-based detection system for altered filamin A (FLNA).
Related indices
More about the company
  1. Stock
  2. Equities
  3. Stock Cassava Sciences, Inc.
  4. Stock Pain Therapeutics, Inc. - Nasdaq